Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$4.64
$0.15(3.87%)
At close: 4:00 PM EDT
$4.64
$0.15(3.87%)
Day’s Range― - ―
52-Week Range$3.00 - $16.20
Previous Close$4.04
Volume3.69M
Average Volume (3M)4.00M
Market Cap
$447.80M
Enterprise Value$743.22M
Total Cash (Recent Filing)$218.01M
Total Debt (Recent Filing)$371.93M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jan 11, 2027EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding147,787,520
10 Day Avg. Volume4,473,675
30 Day Avg. Volume3,999,570
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit2.71
Enterprise Value/Ebitda-40.12
Forecast
1Y Price Target
$5.06Price Target Upside8.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
Record Revenue And Margin ExpansionStrong quarterly revenue and gross-profit growth, alongside wider margins, indicate improving operating execution across the portfolio. If maintained, this combination can strengthen internal funding capacity, support reinvestment in brands and distribution, and improve the company’s earnings foundation over the next several quarters.
International Cannabis PlatformInternational expansion provides Tilray with growth avenues beyond the pressured Canadian adult-use market. Rising European demand, medical distribution, and patient access through Lyphe can broaden the revenue base and make the cannabis segment more resilient as the company adds capacity and market presence.
Debt Reduction And Balance Sheet FlexibilityDebt repayment and relatively moderate leverage improve financial flexibility compared with a more heavily indebted structure. Lower obligations can reduce future interest pressure and preserve room for operating investment, while the balance-sheet improvement provides support as management works toward sustained profitability.
Bears Say
Persistent Losses And Cash BurnNegative operating and free cash flow show that Tilray is still not self-funding its operations despite narrowed losses. Continued cash burn can constrain investment, increase reliance on financing or asset actions, and make durable earnings improvement more important for strengthening the business.
Cannabis Revenue And Pricing PressureCannabis remains exposed to declining revenue and pricing pressure even as reported gross margin improves. Lower realized prices can offset efficiency gains, weaken the segment’s profit contribution, and make growth targets harder to achieve unless product mix, market selection, and international demand continue improving.
Beverage Competition And Route-to-Market RiskA difficult legacy beverage market and changing distributor structure can weaken retail access, increase selling complexity, and pressure brand economics. BrewDog’s contribution currently supports beverage growth, but sustained performance will depend on successful distributor consolidation, focused brands, and profitable channel execution.
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $3.00 and its highest was $16.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $447.80M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jan 11, 2027 which is in 83 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Oct 08, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.181 by -$0.139.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.16.
How many shares outstanding does Tilray have?
Tilray has 147,787,520 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.181. Following the earnings report the stock price went down -3.365%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.06 (8.97% Upside)
$5.06 (8.97% Upside)
Blogger Sentiment
Bullish
TLRY Sentiment 62%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $69.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.57%
12-Months-Change
Fundamentals
Return on Equity
-9.38%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Tilray reported record revenue and gross profit, expanding consolidated and cannabis margins, strong international cannabis and BrewDog growth, U.S. craft beer brand momentum, debt reduction, and reaffirmed fiscal 2027 adjusted EBITDA guidance. These strengths were partly offset by a $40 million net loss, lower adjusted EBITDA, total cannabis revenue contraction, international price compression, Canadian adult-use headwinds, fuel costs, higher investment costs, and continued regulatory and market uncertainty.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$5.06
▲(8.97% Upside)
Technical Analysis
Ownership Overview
2.02% Insiders
0.34% Mutual Funds
0.05% Other Institutional Investors
94.32% Public Companies and
Individual Investors











